Oncologic progression of bone plasmacytomas to multiple myeloma
Fernanda Bertanha1, Gabriela Boufelli, Olavo Pires de Camargo
1Institute of Orthopedics and Traumatology, Hospital das Clínicas, São Paulo University Medical School, São Paulo, SP, Brazil.
Clinics (Sao Paulo, Brazil)
|May 9, 2006
Summary
Patients who progressed from plasmacytoma to multiple myeloma were younger. The study identified a 57% progression rate, with vertebral column injuries being common in both groups.
Area of Science:
- Hematology
- Oncology
Background:
- Plasmacytoma is a rare plasma cell tumor.
- Understanding its progression to multiple myeloma is crucial for patient management.
Purpose of the Study:
- To evaluate clinical aspects, diagnoses, prognostic factors, and progression rates of plasmacytoma to multiple myeloma.
Main Methods:
- Retrospective analysis of 30 patient records (1950-1998) with suspected plasmacytoma.
- Patients were divided into those who progressed to multiple myeloma (n=17) and those who did not (n=13).
- Comparative statistical analysis of clinical data.
Main Results:
- Patients progressing to multiple myeloma were significantly younger (52.3 vs 62.6 years).
- Higher recurrence incidence (75%) in the myeloma progression group.
- Vertebral column injuries were prevalent in both groups; no significant differences in disease duration or survival.
Conclusions:
- Younger age is a factor in plasmacytoma progression to multiple myeloma.
- Vertebral column involvement is common.
- Predictors for survival in plasmacytoma and its progression to multiple myeloma remain undetermined.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...